A carregar...
Bosutinib as a fourth-line therapy for a patient with T315I-positive lymphoid blastic phase chronic myeloid leukemia: A case report
A 35-year-old male was diagnosed with chronic myeloid leukemia in the chronic phase and was prescribed 100 mg daily dasatinib. However, dasatinib was discontinued due to thrombocytopenia, and within six months, the disease progressed to the lymphoid blastic phase. Hyper-cyclophosphamide, vincristine...
Na minha lista:
| Publicado no: | Oncol Lett |
|---|---|
| Main Authors: | , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
D.A. Spandidos
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5452986/ https://ncbi.nlm.nih.gov/pubmed/28599428 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2017.5989 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|